VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+3.91%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$245M
AUM Growth
+$31M
(+15%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
12.58%
Top 10 Holdings %
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49
Top Buys
| 1 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
$1.88M |
| 2 |
DocuSign
DOCU
|
$1.49M |
| 3 |
United Airlines
UAL
|
$1.47M |
| 4 |
Fortinet
FTNT
|
$1.35M |
| 5 |
Spotify
SPOT
|
$1.34M |
Top Sells
| 1 |
Applovin
APP
|
$1.45M |
| 2 |
Expedia Group
EXPE
|
$1.04M |
| 3 |
KKR & Co
KKR
|
$976K |
| 4 |
CME Group
CME
|
$974K |
| 5 |
Corpay
CPAY
|
$948K |
Sector Composition
| 1 | Financials | 29.48% |
| 2 | Technology | 14.86% |
| 3 | Healthcare | 14.81% |
| 4 | Industrials | 11.61% |
| 5 | Consumer Discretionary | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Vir Biotechnology
VIR
$732M
| $70.2K | 0.03% |
9,568
+674
| +8% | +$4.95K |
|
377
Disc Medicine
IRON
$2.11B
| $70.1K | 0.03% |
1,106
-1,247
| -53% | -$79.1K |
|
378
Syndax Pharmaceuticals
SNDX
$1.47B
| $69.8K | 0.03% |
5,278
+827
| +19% | +$10.9K |
|
379
Enliven Therapeutics
ELVN
$1.19B
| $69.5K | 0.03% |
3,091
-1,097
| -26% | -$24.7K |
|
380
Revolution Medicines
RVMD
$7.57B
| $69.2K | 0.03% |
1,582
-739
| -32% | -$32.3K |
|
381
Spyre Therapeutics
SYRE
$1.03B
| $69.2K | 0.03% |
2,972
+124
| +4% | +$2.89K |
|
382
Soleno Therapeutics
SLNO
$3.71B
| $69K | 0.03% |
1,536
-514
| -25% | -$23.1K |
|
383
Arvinas
ARVN
$575M
| $69K | 0.03% |
3,601
+115
| +3% | +$2.21K |
|
384
Prime Medicine
PRME
$663M
| $69K | 0.03% |
23,618
+11,948
| +102% | +$34.9K |
|
385
Recursion Pharmaceuticals
RXRX
$2.01B
| $68.9K | 0.03% |
10,185
+422
| +4% | +$2.85K |
|
386
Zentalis Pharmaceuticals
ZNTL
$126M
| $68.8K | 0.03% |
22,713
+13,030
| +135% | +$39.5K |
|
387
Arcturus Therapeutics
ARCT
$485M
| $68.7K | 0.03% |
4,051
+1,132
| +39% | +$19.2K |
|
|
ITOS
388
DELISTED
iTeos Therapeutics
ITOS
| $68.7K | 0.03% |
8,948
+3,293
| +58% | +$25.3K |
|
|
BCAX
389
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $68.6K | 0.03% |
+3,939
| New | +$68.6K |
|
|
CRGX
390
DELISTED
CARGO Therapeutics
CRGX
| $68.6K | 0.03% |
4,758
-610
| -11% | -$8.8K |
|
391
Capricor Therapeutics
CAPR
$308M
| $68.4K | 0.03% |
+4,957
| New | +$68.4K |
|
392
Immatics
IMTX
$761M
| $68.2K | 0.03% |
9,594
+2,479
| +35% | +$17.6K |
|
393
Akero Therapeutics
AKRO
$3.58B
| $68.1K | 0.03% |
2,449
-1,292
| -35% | -$35.9K |
|
394
Oric Pharmaceuticals
ORIC
$1.06B
| $68.1K | 0.03% |
8,434
-3,563
| -30% | -$28.8K |
|
395
Protagonist Therapeutics
PTGX
$3.77B
| $68K | 0.03% |
1,761
-919
| -34% | -$35.5K |
|
396
Celldex Therapeutics
CLDX
$1.52B
| $67.9K | 0.03% |
2,688
+159
| +6% | +$4.02K |
|
397
Erasca
ERAS
$457M
| $67.8K | 0.03% |
27,031
-15,244
| -36% | -$38.3K |
|
398
Entrada Therapeutics
TRDA
$201M
| $67.8K | 0.03% |
+3,924
| New | +$67.8K |
|
399
Kymera Therapeutics
KYMR
$3.11B
| $67.8K | 0.03% |
1,686
-954
| -36% | -$38.4K |
|
400
Pliant Therapeutics
PLRX
$114M
| $67.6K | 0.03% |
5,133
-2,564
| -33% | -$33.8K |
|